Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2007

View Archived Issues

REVA Medical enrolls first patients in CAD study of bioresorbable stent

FDA approves YM BioSciences' IND for AeroLEF for severe pain

Advancis Pharmaceutical changes name to MiddleBrook Pharmaceuticals

Critical Therapeutics and Dey sign copromotion agreement for Perforomist

NicOx begins third pivotal phase III trail for osteoarthritis of the hip

Preliminary results of SBG for neuroblastoma indicate good safety profile

Preliminary results from two phase II trials of Xcytrin for lung cancer

CombinatoRx discontinues CRx-150 program for rheumatoid arthritis

Final ferumoxytol phase III results expected in summer

Gene Logic to discover new development paths for Lundbeck drug candidates

NovaDel Pharma focuses on programs nearing NDA submission

SkyePharma licenses SKP-1041 to Somnus Therapeutics

Encouraging interim blinded data from phase III SinuNase study

Treanda NDA filing planned for Q3

Promising data from arimoclomol open-label extension trial in ALS reported

Isotechnika completes enrollment for ISA-247 phase IIb kidney transplant trial

E1-I.N.T. yields sustained reductions in HbA1c levels in type 2 diabetes patients

Phase I study supports further clinical evaluation of eltrombopag

Administration of a 11beta-HSD1 inhibitor in the evening improves metabolic parameters in DIO mice

Diabetes snapshots: dipeptidyl peptidase IV inhibitors

Lipid-lowering and antidiabetic activity of DRL-17564, a novel selective PPARgamma modulator

New data on SGLT2 inhibitors sergliflozin, dapagliflozin available

Liraglutide effective in lowering HbA1c in Japanese type 2 diabetes patients

CTA-018 reduces blood levels of parathyroid hormone in phase I trial

Intercell and Novartis sign vaccine development partnership

Interim results for phase I study of ALX-0081

Novel agents for HIV infection reported in recent ViroChem, Pfizer and CNRS patents

New agents targeting hepatitis C described in recent patents

Novel analgesic agents imparted in recent patent literature

Sciele Pharma files sNDA to the FDA for new Sular formulation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...